Based on these considerations, we aimed to determine whether mutational status of TP53 is predictive for pathological complete response (pCR) in the two molecular breast cancer subtypes with the highest TP53 mutations rates, namely TNBC and HER2-positive disease. This evidence concerns the gene ERBB2 and breast cancer.